Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amineptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amineptine SCHEMBL362962 | 1.00 | HTR2C (0.97) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL34086 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL5783484 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL29389410 | 0.99 | HTR2C (1.00) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| SCHEMBL28969679 | 0.82 | HTR2C (0.72) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL8700558 | 0.80 | HTR2C (0.66) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| Amineptine SCHEMBL28280844 | 0.79 | SLC6A3 (0.65) | HTR2CSLC6A3NR1I2OPRM1DRD3 | |
| SCHEMBL9248431 | 0.77 | HTR2C (0.64) | HTR2CSLC6A3OPRM1SMPD1KMT2A | |
| SCHEMBL390761 | 0.74 | HTR2C (0.60) | HTR2CSLC6A3KMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL19180243 | 0.74 | NR1I2 (0.78) | HTR2CSLC6A3NR1I2OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| CN-102595894-A | Compounds that treat malaria and prevent malaria transmission | USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES | 2012-07-18 | — | — | CN | claimed |
| CN-102143961-A | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2011-08-03 | — | — | CN | claimed |
| CN-101910157-A | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2010-12-08 | — | — | CN | claimed |
| CN-101809000-A | Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition | SOLVAY PHARM BV | 2010-08-18 | — | — | CN | claimed |
| CN-101778819-A | Indole indane amide compounds and method as the CB2 agonist | BRISTOL MYERS SQUIBB CO | 2010-07-14 | — | — | CN | claimed |
| CN-101484152-A | Therapeutic combination for painful medical conditions | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-07-15 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| CN-1747719-A | Topical compositions and methods for treating pain | EPICEPT CORP (US) | 2006-03-15 | — | — | CN | claimed |
| CN-1729160-A | Medicine for treating chronic pain | NICOX SA (FR) | 2006-02-01 | — | — | CN | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | ENTERIN, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-5672356-A | Bioadhesive pharmaceutical composition for the controlled release of active principles | ADIR ET COMPAGNIE (FR) | 1997-09-30 | — | — | US | disclosed |
| CN-1159950-A | Bioadhesive pharmaceutical composition for controlled release of active principles | ADIR (FR) | 1997-09-24 | — | — | CN | disclosed |
| CN-1091635-A | As the 2-amino-6-n-pro-pyl-amino-4,5,6 with anti-strongly fragrant drugs with function, the 7-tetrahydro benzothiazol is used | BOEHRINGER INGELHEIM KG (DE) | 1994-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | HTR2C 162/4885SLC6A3 220/4885NR1I2 1083/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | HTR2C 7/4885SLC6A3 30/4885NR1I2 916/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | HTR2C 1188/4885SLC6A3 1263/4885NR1I2 144/4885 |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | CYP17A1, HSD17B13, HSD17B7 | HTR2C 3934/4885SLC6A3 3773/4885NR1I2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.